1892-54-2

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 24, p. 421, 1959 DOI: 10.1021/jo01085a607

Safety Profile

Questionable carcinogen with experimental tumorigenic data.Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. See also AROMATIC AMINES

InChI:InChI=1/C14H11N/c15-12-8-7-11-6-5-10-3-1-2-4-13(10)14(11)9-12/h1-9H,15H2

Upstream product

• 605-87-8 3-Phenanthrol 
• 17024-19-0 3-nitro-phenanthrene 
• 106782-35-8 9-bromo-3-nitro-phenanthrene 
• 4120-78-9 N-(phenanthren-3-yl)acetamide 
• 1506-20-3 9,10-Dichlor-3-nitrophenanthren 
• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 
• 85-01-8 phenanthrene 
• 2039-76-1 1-(phenanthren-3-yl)ethanone 
• 5968-50-3 1-(phenanthren-3-yl)ethanone oxime 

Downstream Products

• 4120-78-9 N-(phenanthren-3-yl)acetamide 
• 440-40-4 3-Fluorophenanthrene 
• 268218-25-3 6-chloronaphtho[2',1':4,5]thieno[2,3-c]naphtho[1,2-f]quinoline 
• 153935-95-6 6-chloro<1>benzothieno<2,3-c>naphtho<1,2-f>quinoline 
• 496806-13-4 7-chloro<1>benzothieno<2,3-c>naphtho<2,1-g>quinoline 
• 56961-99-0 3-chlorophenanthrene-9,10-dione 

Relevant academic research and scientific papers

The electronic element for phenanthrene compd. org.

The invention relates to specific phenanthrenes, the use of the compound in an electronic device, and an electronic device containing at least one of said compounds. The invention further relates to a method for producing the compound and a formulation an

Substituted tetraarylbenzenes

The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed

2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

METHODS FOR TREATING OR PREVENTING NEOPLASIAS

The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors

Phenanthrene imidazole 3 (MF63) has been identified as a novel potent, selective, and orally active mPGES-1 inhibitor. This new series was developed by lead optimization of a hit from an internal HTS campaign. Compound 3 is significantly more potent than the previously reported indole carboxylic acid 1 with an A549 whole cell IC50 of 0.42 μM (50% FBS) and a human whole blood IC50 of 1.3 μM. It exhibited a significant analgesic effect in a guinea pig hyperalgesia model when orally dosed at 30 and 100 mg/kg.

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula I INSERT FORMULA I FROM CLAIM 1 or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Chemical process

Aromatic amines (e.g., aniline) are selectively alkylated in an ortho nuclear position by reaction with an olefin (e.g., ethylene) in the presence of an aluminum anilide catalyst. Hydrogen halides (e.g., HCl) are added to increase the reaction rate.